Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 02, 2025 07:00 ET | Source: Pasithea

Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

Extends cash runway through at least the first half of 2028Led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle...
November 28, 2025 09:20 ET | Source: Pasithea

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

Extends cash runway through at least the first half of 2028Led by Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron...
November 21, 2025 12:35 ET | Source: Pasithea

Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients

Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients
September 16, 2025 07:03 ET | Source: Pasithea

Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Pasithea Tx (Nasdaq: KTTA) activates South Korea trial sites, dosing first NF1 patient in Phase 1/1b NF1 study at Asan Medical Ctr. and Severance Hospital.
August 28, 2025 07:02 ET | Source: Pasithea

Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Pasithea Tx (Nasdaq: KTTA) to present PAS-004 clinical progress at H.C. Wainwright Global Investment Conference on Sept. 10, 2025 in NYC.